Cindy Jiang, MD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | University of Missouri-Kansas City, Kansas City, Missouri, US, Doctor of Medicine |
| 2018 | University of Missouri-Kansas City, Kansas City, Missouri, US, Bachelor of Liberal Arts with Chemistry Minor |
Postgraduate Training
| 2022-2025 | Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer, Houston, Texas |
| 2019-2022 | Residency, Internal Medicine, University of Michigan, Ann Arbor, Michigan |
Licenses & Certifications
| 2024 | DEA Practitioner |
| 2022 | American Board of Internal Medicine |
| 2022 | Texas Medical Board |
Honors & Awards
| 2024 - Present | 2024 ASCO/AACR Methods in Clinical Cancer Research |
| 2024 - Present | GU ASCO Merit Award |
| 2019 - Present | UMKC Women in Medicine Scholarship Achievement Citation |
| 2018 - Present | 2nd place at Vijay Babu Raydu Quality and Patient Safety Day |
| 2013 - Present | Intel Science and Engineering Fair 2nd Place Grand Award |
| 2013 - Present | MIT Laboratory Ceres Connection Minor Planet Naming |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol 8(2):258-262, 2025. e-Pub 2025. PMID: 39709257.
- Jiang CY, Zhao L, Green MD, Ravishankar S, Towlerton AMH, Scott AJ, Raghavan M, Cusick MF, Warren EH, Ramnath N. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer. Sci Rep 14(1):345, 2024. e-Pub 2024. PMID: 38172168.
- Jiang CY, Zhao L, Schuetze SM, Chugh R. Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. Oncologist 27(7):595-599, 2022. e-Pub 2022. PMID: 35589095.
- Jiang CY, Strohbehn GW, Dedinsky RM, Raupp SM, Pannecouk BM, Yentz SE, Ramnath N. Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts. JCO Oncol Pract 17(9):e1362-e1374, 2021. e-Pub 2021. PMID: 34406817.
- Jiang CY, Niu Z, Green MD, Zhao L, Raupp S, Pannecouk B, Brenner DE, Nagrath S, Ramnath N. It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34321277.
- Jiang CY, El-Kouri NT, Elliot D, Shields J, Caram MEV, Frankel TL, Ramnath N, Passero VA. Telehealth for Cancer Care in Veterans: Opportunities and Challenges Revealed by COVID. JCO Oncol Pract 17(1):22-29, 2021. e-Pub 2021. PMID: 32970512.
Patient Reviews
CV information above last modified August 26, 2025